$PCRX
Pacira Biosciences Inc Stock $pcrx

$pcrx Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000139681420000020 Filed on May 07, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$105.7M	$91.31M
YoY Change	15.74%	22.39%
Cost Of Revenue	$29.73M	$27.30M
YoY Change	8.9%	19.31%
Gross Profit	$75.95M	$64.01M
YoY Change	18.66%	23.76%
Gross Profit Margin	71.87%	70.1%
Selling, General & Admin	$44.78M	$47.31M
YoY Change	-5.34%	7.05%
% of Gross Profit	58.96%	73.9%
Research & Development	$15.82M	$14.38M
YoY Change	9.98%	0.04%
% of Gross Profit	20.83%	22.47%
Depreciation & Amortization	$4.821M	$3.600M
YoY Change	33.92%	30.34%
% of Gross Profit	6.35%	5.62%
Operating Expenses	$60.60M	$90.23M
YoY Change	-32.84%	10.66%
Operating Profit	$17.09M	$1.079M
YoY Change	1484.24%	-115.55%
Interest Expense	$6.022M	$5.814M
YoY Change	3.58%	12.74%
% of Operating Profit	35.23%	538.83%
Other Income/Expense, Net	-$8.537M	-$3.597M
YoY Change	137.34%	-2.99%
Pretax Income	$8.557M	-$2.518M
YoY Change	-439.83%	-76.35%
Income Tax	$400.0K	$253.0K
% Of Pretax Income	4.67%
Net Earnings	$8.159M	-$2.771M
YoY Change	-394.44%	-74.05%
Net Earnings / Revenue	7.72%	-3.03%
Basic Earnings Per Share	$0.19	-$0.07
Diluted Earnings Per Share	$0.19	-$0.07
COMMON SHARES
Basic Shares Outstanding	42.03M shares	41.24M shares
Diluted Shares Outstanding	42.79M shares	41.24M shares

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$318.5M	$412.4M
YoY Change	-22.77%	21.37%
Cash & Equivalents	$54.59M	$215.0M
Short-Term Investments	$263.9M	$197.4M
Other Short-Term Assets	$14.50M	$9.400M
YoY Change	54.26%	22.08%
Inventory	$59.67M	$47.03M
Prepaid Expenses
Receivables	$38.99M	$39.77M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$431.6M	$508.7M
YoY Change	-15.15%	21.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$108.1M	$107.1M
YoY Change	0.98%	-1.99%
Goodwill	$99.50M	$62.00M
YoY Change	60.48%	7.84%
Intangibles	$102.4M
YoY Change
Long-Term Investments	$42.10M	$14.10M
YoY Change	198.58%	-60.61%
Other Assets		$560.0K
YoY Change		-26.22%
Total Long-Term Assets	$389.8M	$210.5M
YoY Change	85.19%	3.53%
TOTAL ASSETS
Total Short-Term Assets	$431.6M	$508.7M
Total Long-Term Assets	$389.8M	$210.5M
Total Assets	$821.4M	$719.2M
YoY Change	14.21%	15.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.85M	$13.37M
YoY Change	18.56%	-10.35%
Accrued Expenses	$44.72M	$39.70M
YoY Change	12.65%	20.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$80.31M	$58.99M
YoY Change	36.14%	21.96%
LONG-TERM LIABILITIES
Long-Term Debt	$310.1M	$294.4M
YoY Change	5.33%	5.26%
Other Long-Term Liabilities	$1.535M	$8.993M
YoY Change	-82.93%	-41.84%
Total Long-Term Liabilities	$1.535M	$8.993M
YoY Change	-82.93%	-41.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$80.31M	$58.99M
Total Long-Term Liabilities	$1.535M	$8.993M
Total Liabilities	$447.3M	$391.6M
YoY Change	14.22%	14.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$391.2M	-$391.2M
YoY Change	0.02%	-1.83%
Common Stock	$42.00K	$41.00K
YoY Change	2.44%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares		0.000 shares
Shareholders Equity	$374.0M	$327.5M
YoY Change
Total Liabilities & Shareholders Equity	$821.4M	$719.2M
YoY Change	14.21%	15.61%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	$8.159M	-$2.771M
YoY Change	-394.44%	-74.05%
Depreciation, Depletion And Amortization	$4.821M	$3.600M
YoY Change	33.92%	30.34%
Cash From Operating Activities	$6.208M	$3.499M
YoY Change	77.42%	-230.07%
INVESTING ACTIVITIES
Capital Expenditures	$6.724M	$2.018M
YoY Change	233.2%	-61.07%
Acquisitions
YoY Change
Other Investing Activities	-$21.84M	$80.50M
YoY Change	-127.13%	-1675.34%
Cash From Investing Activities	-$28.57M	$78.48M
YoY Change	-136.4%	-862.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.281M	$530.0K
YoY Change	-341.7%	26.49%
NET CHANGE
Cash From Operating Activities	$6.208M	$3.499M
Cash From Investing Activities	-$28.57M	$78.48M
Cash From Financing Activities	-$1.281M	$530.0K
Net Change In Cash	-$23.64M	$82.51M
YoY Change	-128.65%	19592.12%
FREE CASH FLOW
Cash From Operating Activities	$6.208M	$3.499M
Capital Expenditures	$6.724M	$2.018M
Free Cash Flow	-$516.0K	$1.481M
YoY Change	-134.84%	-118.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001396814
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-35060
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	PACIRA BIOSCIENCES, INC.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	51-0619477
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5 Sylvan Way, Suite 300
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Parsippany
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07054
CY2020Q1	dei	City Area Code CityAreaCode	973
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	254-3560
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2020Q1	dei	Trading Symbol TradingSymbol	PCRX
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42120749	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54589000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78228000	USD
CY2020Q1	us-gaap	Short Term Investments ShortTermInvestments	263875000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	213722000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	38988000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	47530000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	59666000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	58296000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14476000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10781000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	431594000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	408557000	USD
CY2020Q1	us-gaap	Long Term Investments LongTermInvestments	35120000	USD
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	64798000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	108105000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	104681000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	37613000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38124000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	99547000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	99547000	USD
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	102421000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	104387000	USD
CY2020Q1	us-gaap	Summary Of Investments Other Than Investments In Related Parties Carrying Amount SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount	6979000	USD
CY2019Q4	us-gaap	Summary Of Investments Other Than Investments In Related Parties Carrying Amount SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount	10971000	USD
CY2020Q1	us-gaap	Assets Assets	821379000	USD
CY2019Q4	us-gaap	Assets Assets	831065000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	15850000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12799000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	44717000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	70427000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3968000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4935000	USD
CY2020Q1	pcrx	Contingent Consideration Current ContingentConsiderationCurrent	14041000	USD
CY2019Q4	pcrx	Contingent Consideration Current ContingentConsiderationCurrent	18179000	USD
CY2020Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	1737000	USD
CY2019Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	1333000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	80313000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	107673000	USD
CY2020Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	310078000	USD
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	306045000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40189000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40938000	USD
CY2020Q1	pcrx	Contingent Consideration Noncurrent ContingentConsiderationNoncurrent	15227000	USD
CY2019Q4	pcrx	Contingent Consideration Noncurrent ContingentConsiderationNoncurrent	19963000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1535000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1502000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	447342000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	476121000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42116545	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42116545	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41908148	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41908148	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	42000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	42000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	766280000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	753978000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-391239000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-399398000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1046000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	322000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	374037000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	354944000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	821379000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	831065000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	105684000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	374037000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	91313000	USD
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	29732000	USD
CY2019Q1	us-gaap	Cost Of Revenue CostOfRevenue	27303000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15819000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14384000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	44780000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	47305000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1967000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2020Q1	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	3708000	USD
CY2019Q1	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-1242000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	88590000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	90234000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	17094000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1079000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1589000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2156000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	6022000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	5814000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4104000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	61000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8537000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3597000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8557000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2518000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	398000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	253000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	8159000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-2771000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.19
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42032000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41240000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42785000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41240000	shares
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	8159000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-2771000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1368000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	462000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1368000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	462000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6791000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2309000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	354944000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3455000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8847000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1368000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	8159000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	321226000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1557000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7434000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	462000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-2771000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	327519000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	8159000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-2771000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4821000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3600000	USD
CY2020Q1	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	439000	USD
CY2019Q1	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	420000	USD
CY2020Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3594000	USD
CY2019Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3345000	USD
CY2020Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-22000	USD
CY2019Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8847000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7434000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3874000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2020Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-3971000	USD
CY2019Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8542000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1766000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1370000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1540000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3674000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1644000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2868000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1442000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-24700000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5166000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1173000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-51000	USD
CY2020Q1	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	264000	USD
CY2019Q1	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	0	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6208000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3499000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6724000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2018000	USD
CY2020Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	72610000	USD
CY2019Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	22688000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	50768000	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	103187000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28566000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	78481000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3455000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1101000	USD
CY2020Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
CY2019Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	338000	USD
CY2020Q1	pcrx	Conversionofprincipalandequitycomponentofconvertibleseniornotes Conversionofprincipalandequitycomponentofconvertibleseniornotes	0	USD
CY2019Q1	pcrx	Conversionofprincipalandequitycomponentofconvertibleseniornotes Conversionofprincipalandequitycomponentofconvertibleseniornotes	233000	USD
CY2020Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	4736000	USD
CY2019Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1281000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	530000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23639000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	82510000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78228000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132526000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54589000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	215036000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	5000	USD
CY2020Q1	pcrx	Increase Decreasein Accrued Fixed Assets IncreaseDecreaseinAccruedFixedAssets	423000	USD
CY2019Q1	pcrx	Increase Decreasein Accrued Fixed Assets IncreaseDecreaseinAccruedFixedAssets	37000	USD
CY2020Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104745000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90906000	USD
CY2020Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	23162000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	20019000	USD
CY2020Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7757000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	14407000	USD
CY2020Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	28747000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	23870000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	59666000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	58296000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	186299000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	180121000	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	78194000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	75440000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	108105000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	104681000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	2900000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	3600000	USD
CY2020Q1	pcrx	Foreign Property Plantand Equipment Net ForeignPropertyPlantandEquipmentNet	64000000.0	USD
CY2019Q4	pcrx	Foreign Property Plantand Equipment Net ForeignPropertyPlantandEquipmentNet	64800000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1564000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1443000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	448000	USD
CY2019Q1	us-gaap	Variable Lease Cost VariableLeaseCost	381000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	2012000	USD
CY2019Q1	us-gaap	Lease Cost LeaseCost	1824000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	2759000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	2050000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	174000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	34780000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y2M23D
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0755
CY2020Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Remainder Of Fiscal Year LesseeOperatingLeaseLeaseNotYetCommencedLiabilityRemainderOfFiscalYear	7124000	USD
CY2020Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due Year Two LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueYearTwo	4415000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	6116000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6330000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5875000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6013000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	6155000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	32830000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	63319000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	19162000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	44157000	USD
CY2020Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Number Of Contracts LesseeOperatingLeaseLeaseNotYetCommencedNumberOfContracts	1	contract
CY2020Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due Year Three LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueYearThree	4548000	USD
CY2020Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due Year Four LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueYearFour	4684000	USD
CY2020Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due Year Five LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueYearFive	4825000	USD
CY2020Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability Due After Year Five LesseeOperatingLeaseLeaseNotYetCommencedLiabilityDueAfterYearFive	29242000	USD
CY2020Q1	pcrx	Lessee Operating Lease Lease Not Yet Commenced Liability LesseeOperatingLeaseLeaseNotYetCommencedLiability	54838000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	99500000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	99500000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	110090000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7669000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	102421000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	110090000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5703000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	104387000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000.0	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	5900000	USD
CY2020Q1	pcrx	Finite Lived Intangible Assets Amortization Expense Annual Amount From2020 To2032 FiniteLivedIntangibleAssetsAmortizationExpenseAnnualAmountFrom2020To2032	7900000	USD
CY2020Q1	pcrx	Finite Lived Intangible Assets Amortization Expense Annual Amount In2033 FiniteLivedIntangibleAssetsAmortizationExpenseAnnualAmountIn2033	2200000	USD
CY2020Q1	pcrx	Settlement Period Convertible Debt Conversion Request SettlementPeriodConvertibleDebtConversionRequest	P40D
CY2020Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0781
CY2019Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0781
CY2020Q1	us-gaap	Share Price SharePrice	33.53
CY2020Q1	pcrx	Total Milestone Payments Yet To Be Paidin Connectionwith Myo Science Acquisition TotalMilestonePaymentsYetToBePaidinConnectionwithMyoScienceAcquisition	68000000.0	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10000000.0	USD
CY2020Q1	us-gaap	Interest Receivable InterestReceivable	1600000	USD
CY2019Q4	us-gaap	Interest Receivable InterestReceivable	1000000.0	USD
CY2020Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	6100000	USD
CY2019Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	10000000.0	USD
CY2020Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	4000000.0	USD
CY2019Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2020Q1	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	customer
	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	customer
CY2020Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8847000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7434000	USD
CY2020Q1	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	6225000	USD
CY2019Q1	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	5121000	USD
CY2020Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	2402000	USD
CY2019Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	2107000	USD
CY2020Q1	pcrx	Compensationexpensefromemployeestockpurchaseplan Compensationexpensefromemployeestockpurchaseplan	220000	USD
CY2019Q1	pcrx	Compensationexpensefromemployeestockpurchaseplan Compensationexpensefromemployeestockpurchaseplan	206000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8847000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7434000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	20.97
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.85
CY2020Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	8159000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-2771000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42032000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41240000	shares
CY2020Q1	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	585000	shares
CY2019Q1	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	0	shares
CY2020Q1	pcrx	Incremental Common Shares Attributableto Dilutive Effectof Restricted Stock Units IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits	168000	shares
CY2019Q1	pcrx	Incremental Common Shares Attributableto Dilutive Effectof Restricted Stock Units IncrementalCommonSharesAttributabletoDilutiveEffectofRestrictedStockUnits	0	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42785000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41240000	shares
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.19
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5385000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6388000	shares
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	13046000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1819000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4489000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4337000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8557000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2518000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	400000	USD
CY2019Q1	pcrx	Income Tax Provision IncomeTaxProvision	-300000	USD
CY2019Q1	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	100000	USD
CY2020Q1	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	100000	USD
CY2019Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	81000	USD
CY2019Q4	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	558000	USD
CY2019Q4	us-gaap	Discontinued Operation Amounts Of Material Contingent Liabilities Remaining DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining	639000	USD
CY2020Q1	us-gaap	Severance Costs1 SeveranceCosts1	0	USD
CY2020Q1	us-gaap	Costs Incurred Asset Retirement Obligation Incurred CostsIncurredAssetRetirementObligationIncurred	166000	USD
CY2020Q1	us-gaap	Payments For Postemployment Benefits PaymentsForPostemploymentBenefits	0	USD
CY2020Q1	us-gaap	Asset Retirement Obligation Liabilities Settled AssetRetirementObligationLiabilitiesSettled	292000	USD
CY2020Q1	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	292000	USD
CY2020Q1	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	81000	USD
CY2020Q1	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	432000	USD
CY2020Q1	us-gaap	Discontinued Operation Amounts Of Material Contingent Liabilities Remaining DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining	513000	USD
CY2019Q4	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	3500000	USD

Files In Submission

Name	View Source	Status
0001396814-20-000020-index-headers.html	Edgar Link	pending
0001396814-20-000020-index.html	Edgar Link	pending
0001396814-20-000020.txt	Edgar Link	pending
0001396814-20-000020-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pcrx-20200331.htm	Edgar Link	pending
pcrx-20200331.xsd	Edgar Link	pending
pcrx-20200331_cal.xml	Edgar Link	unprocessable
pcrx-20200331_def.xml	Edgar Link	unprocessable
pcrx-20200331_g1.jpg	Edgar Link	pending
pcrx-20200331_htm.xml	Edgar Link	completed
pcrx-20200331_lab.xml	Edgar Link	unprocessable
pcrx-20200331_pre.xml	Edgar Link	unprocessable
pcrx-3312020xex101.htm	Edgar Link	pending
pcrx-3312020xex102.htm	Edgar Link	pending
pcrx-3312020xex103.htm	Edgar Link	pending
pcrx-3312020xex311.htm	Edgar Link	pending
pcrx-3312020xex312.htm	Edgar Link	pending
pcrx-3312020xex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCRX
Pacira Biosciences Inc Stock $pcrx

2020 Q1 Form 10-Q Financial Statement

#000139681420000020 Filed on May 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX Pacira Biosciences Inc Stock $pcrx

2020 Q1 Form 10-Q Financial Statement

#000139681420000020 Filed on May 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX
Pacira Biosciences Inc Stock $pcrx